A new stem cell therapy has repaired blinding damage to the cornea in 93% of patients in an early clinical trial. The cornea is the clear dome that covers the front of the eye and helps to focus light ...

In this new process, stem cells taken from a person's healthy eye can be used to rebuild the cornea in their damaged eye, researchers reported March 4 in the journal Nature Communications. The ...

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

Researchers successfully pulled off the first eye stem cell transplants to help heal cornea damage, and the results speak for ...

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed ...

The study was led by Harvard Medical School and Massachusetts Eye and Ear researchers and surgeons. The researchers reported ...

HDAC6 is upregulated in corneal diseases and causes ENKD1 deacetylation at lysine 98. Deacetylation of ENKD1 blocks its ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

Novel stem cell therapy repairs 'irreversible' corneal damage in clinical trial Date: March 4, 2025 Source: Mass Eye and Ear Summary: Results from a phase 1/2 clinical trial of a novel stem cell ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...